SCHEMBL13402177

SCHEMBL13402177

O=C(CCCOc1ccc(Cl)cc1Cl)N1CCCC(O)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 10/20 0.64
KMT2A Q03164 3/20 0.64
ALDH1A1 P00352 2/20 0.64
MEN1 O00255 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.59
MAPT P10636 6/20 0.58
TSHR P16473 3/20 0.58
USP2 O75604 1/20 0.58
NPSR1 Q6W5P4 4/20 0.57
RAB9A P51151 3/20 0.57
NPC1 O15118 1/20 0.57
HTT P42858 2/20 0.56
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
HSD17B10 Q99714 1/20 0.55
GAA P10253 1/20 0.54
ALOX12 P18054 1/20 0.54
ENPP2 Q13822 1/20 0.53
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13401521 0.91 HPGD (0.67) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL24163547 0.88 HPGD (0.65) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL24163544 0.86 HPGD (0.79) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL3456248 0.85 HPGD (0.77) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL3281854 0.82 HPGD (0.67) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL3276219 0.82 HPGD (0.63) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL2829098 0.80 HPGD (0.67) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL4378295 0.80 HPGD (0.70) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL4381856 0.79 HPGD (0.69) HPGDKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL24163542 0.78 HPGD (1.00) HPGDKMT2AALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087543-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES VTVX HOLDINGS II LLC 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087543-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD17B1, HSD11B2 HPGD 34/4885KMT2A 4062/4885ALDH1A1 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.